Cancer Research Communications | American Association for Cancer Research

Skip Nav Destination

Editors-In-Chief

Elaine R. Mardis, PhD
Nationwide Children's Hospital
The Ohio State University

Lillian L. Siu, MD
Princess Margaret Cancer Centre
University of Toronto

SUBMIT TO JOURNAL EDITORS

Editors-In-Chief

Elaine R. Mardis, PhD
Nationwide Children's Hospital
The Ohio State University

Lillian L. Siu, MD
Princess Margaret Cancer Centre
University of Toronto

SUBMIT TO JOURNAL EDITORS

Editors' Corner

Advances in Patient Care and Outcomes Through Clinical Research and Trials

The American Society for Clinical Oncology (ASCO) annual meeting was held June 3-7, 2022, in Chicago, IL. The meeting was overall very exciting, not least of all the opportunity to be there in person, engage with the oncologic community...(read more)

Journal Sections

Cancer Research Communications welcomes high-quality research spanning the full spectrum of cancer science and medicine. This open access journal expands the AACR journal portfolio, stimulates the exchange of new ideas and approaches, and provides a rapid publication pathway. The below sections reflect the breadth of this new journal’s scope.

Molecular and Cellular Biology

Tumor Biology

Immuno-oncology

Emerging Technologies and Data Science

Therapeutic Research and Development

Precision Medicine and Biomarkers

Clinical Research and Trials

Epidemiology and Prevention

Health Disparities and Outcomes Research

Featured Articles

Molecular and Cellular Biology

Loss of vascular endothelial glutaminase inhibits tumor growth and metastasis, and increases sensitivity to chemotherapy

Verra M. Ngwa, Deanna N Edwards et al.

Glutamine is the most abundant non-essential amino acid in blood stream; yet it's concentration in tumor interstitium is markedly lower than that in the serum, reflecting the huge demand of various cell types in tumor microenvironment for glutamine. While many studies have investigated glutamine metabolism in tumor ...

Browse Section

Go to Section

Tumor Biology

Loss of vascular endothelial glutaminase inhibits tumor growth and metastasis, and increases sensitivity to chemotherapy

Verra M. Ngwa, Deanna N Edwards et al.

Browse Section

Go to Section

Immuno-oncology

A TCR-like CAR promotes sensitive antigen recognition and controlled T cell expansion upon mRNA vaccination

Matthias Birtel, Ralf-Holger Voss et al.

Chimeric antigen receptor (CAR) T cells are efficacious in patients with B cell malignancies, while their activity is limited in patients with solid tumors. We developed a novel heterodimeric TCR-like CAR (TCAR) designed to achieve optimal chain pairing and integration into the T cell CD3 signaling complex. The TCAR ...

Browse Section

Go to Section

Emerging Technologies and Data Science

Assessment of Colorectal Cancer Screening Disparities in U.S. Men and Women Using a Demographically Representative Sample

Sumit K. Shah, Marie-Rachelle Narcisse et al.

Timely receipt of colorectal cancer screening can reduce morbidity and mortality. This is the first known study to adopt Andersen's model of health services use to identify factors associated with colorectal cancer screening among U.S. adults. The data from National Health Interview Survey from 2019 was utilized to ...

Browse Section

Go to Section

Therapeutic Research and Development

8-Azaadenosine and 8-Chloroadenosine are not Selective Inhibitors of ADAR

Kyle A. Cottrell, Luisangely Soto-Torres et al.

The RNA editing enzyme ADAR is an attractive therapeutic target for multiple cancers. Through its deaminase activity, ADAR edits adenosine to inosine in double-stranded RNAs. Loss of ADAR in some cancer cell lines causes activation of the type I IFN pathway and the PKR translational repressor, leading to inhibition of ...

Browse Section

Go to Section

Precision Medicine and Biomarkers

Comprehensive Immunoprofiling of High-Risk Oral Proliferative and Localized Leukoplakia

Glenn J. Hanna, Alessandro Villa et al.

Oral leukoplakia is common and may, in some cases, progress to carcinoma. Proliferative leukoplakia is a progressive, often multifocal subtype with a high rate of malignant transformation compared with the more common localized leukoplakia. We hypothesized that the immune microenvironment and gene expression patterns ...

Browse Section

Go to Section